Clinical Trial Update: The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.

View source ↗

Summary

A clinical trial update collecting data on liver cancer patients treated with pembrolizumab, atezolizumab, or lenvatinib after 2019 and analyzing prognostic out…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• Tecentriq (atezolizumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Liver Cancer, Pembrolizumab | Status: ACTIVE_NOT_RECRUITING